PERTH, Australia – Australia's biopharma and medical device industries breathed a collective sigh of relief that the Australian Government's 2017 budget announced May 9 left the much-loved R&D tax incentive untouched.
PERTH, Australia – The TGA is seeking industry comments on its proposal to beef up sanctions and penalties as part of its overhaul of drug and device regulations.
PERTH, Australia – Although CEOs of life sciences companies in Australia said that 2016 was their strongest year yet, that optimism was dampened by uncertainty surrounding government policy on R&D tax incentives, according to AusBiotech's annual CEO survey.
PERTH, Australia – The TGA is seeking industry comments on its proposal to beef up sanctions and penalties as part of its overhaul of drug and device regulations. Some of the proposals relate to suggestions from the expert panel review that would introduce public warnings for advertising noncompliance.
PERTH, Australia – Although CEOs of life sciences companies in Australia said that 2016 was their strongest year yet, that optimism was dampened by uncertainty surrounding government policy on R&D tax incentives, according to AusBiotech's annual CEO survey.
PERTH, Australia – The pharma industry largely supports the Therapeutic Goods Administration's (TGA) update to its orphan drug regulations, expected to become effective July 1, though industry stakeholders offered some suggestions for modifications, mostly regarding eligibility criteria for orphan designation and the time lapse for the validity period.
PERTH, Australia – The pharma industry largely supports the Therapeutic Goods Administration's (TGA) update to its orphan drug regulations, expected to become effective July 1, though industry stakeholders offered some suggestions for modifications, mostly regarding eligibility criteria for orphan designation and the time lapse for the validity period.
